KCT0002804进行中（未招募）未知
Efficacy of fixed monthly dosing of Lucentis® (Ranibizumab) on subretinal fluid associated with persistent retinal pigment epithelial detachment in neovascular age-related macular degeneration: An exploratory study
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 50(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. age older than 50 years 2. known choroidal neovascularization secondary to age related macular degeneration as demonstrated by fluorescein angiography 3. persistent pigment epithelial defect (with possible serous component) and subretinal fluid due to choroidal neovascularization
排除标准
- •1. history of previous vitrectomy 2. prior photodynamic treatment and/or photocoagulation on macular region 3. patients had other retinal conditions other than typical AMD 4. previous history of systemic of ocular corticosteroid medication 5. active intraocular inflammation or systemic infection.
研究者
相似试验
已完成
4 期
Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular DegenerationWet Macular DegenerationNCT02944227Seoul National University Hospital20
进行中（未招募）
不适用
A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD.Chronic Obstructive Pulmonary DiseaseEUCTR2010-022796-62-SEGlaxoSmithKline Research & Development Ltd425
进行中（未招募）
不适用
A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD.Chronic Obstructive Pulmonary DiseaseEUCTR2010-022796-62-SKGlaxoSmithKline Research & Development Ltd425
进行中（未招募）
不适用
A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD.Chronic Obstructive Pulmonary DiseaseEUCTR2010-022796-62-NLGlaxoSmithKline Research & Development Ltd425
已完成
2 期
A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD.COPD10038716NL-OMON36391GlaxoSmithKline35